TEM +12% on Q3 beat: revenue +23%, oncology volumes accelerate, guide raised

Master pure market mechanics, Level 2 data analysis, liquidity pools, and micro-timeframe execution. Discuss real-time order flow and institutional setups.
Post Reply
LondonNewsTrader
Posts: 549
Joined: Sat Sep 05, 2026 10:13 pm

TEM +12% on Q3 beat: revenue +23%, oncology volumes accelerate, guide raised

Post by LondonNewsTrader »

Tempus AI is up around 9-12% today after a Q3 beat on earnings, revenue and adjusted EBITDA.

The numbers
- Revenue up 23% to $411.5m
- Data and applications grew 33%, and oncology volume growth accelerated to 32%
- 2026 revenue forecast raised; adjusted EBITDA outlook reiterated

For scalpers
- TEM is a high-beta AI-healthcare name that moves well past its fundamentals in both directions, so expect wide intraday ranges and quick reversals
- The acceleration in oncology volumes is the detail bulls will lean on; the reiterated (not raised) EBITDA guide is what sceptics will point at
- Check short interest before chasing. Squeezy names can give back half the gap once early shorts have covered

Source: [CNBC midday movers](https://www.cnbc.com/2026/11/02/stocks- ... -rivn.html)

Anyone trading TEM today, or does the AI-healthcare label make it too noisy to scalp? Do you think the gap holds into tomorrow?
Post Reply